Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06088472 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 10 words
    • Site details revised
  2. Phase: Early Phase 1 to Phase 1v5 Show 8 more changesShow less
    • Enrollment target: 19 to 12
    • Primary and study completion dates: Apr 21, 2024 to Dec 31, 2027
    • Primary endpoint revised
    • Trial status: Completed to Recruiting
    • Eligibility criteria shortened, about 21 words
    • Secondary endpoints expanded, about 18 words
    • Study site revised
    • Collaborators expanded, about 7 words
  3. Primary endpoint revisedv4
  4. Primary endpoint revised
    • Eligibility criteria shortened, about 48 words
    v3
  5. Trial status: Recruiting to Completed
    • Enrollment target: estimated 20 to confirmed 19
    • Site details revised
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-center, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, NMA-LD chemotherapy , treatment and observation period, and follow-up period.
Trial Details
NCT Number NCT06088472
Lead Sponsor Grit Biotechnology
Collaborators: The Affiliated Hospital of Xuzhou Medical University
Conditions
(from sponsor)		 Solid Tumors, Adult
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov